Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Duravelo-2 in locally advanced or metastatic urothelial cancer
NL-OMON59744Phase 2Completed
- Sponsor
- Bicycle Therapeutics
- Start
- Sep 2024
- Modality
- Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of zelenectide pevedotin, pembrolizumab, gemcitabine, cisplatin, carboplatin and 1 more in transitional cell carcinoma (TCC) (4 cohorts), sponsored by Bicycle Therapeutics. Started Sep 2024; status: completed.
02
Drugs
03
Conditions
transitional cell carcinoma (TCC)
Beyond the preview
Go deeper on NL-OMON59744.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON59744.